Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease.
DNSP-11 showed increased dopamine turnover in normal rats and protective effects in a Parkinson's disease model, but these findings are based on animal studies and may not translate to humans.
Where it sits
this study against the rest of the dnsp-11 (dopamine neuron stimulating peptide-11) corpusSummary and findings
This study evaluated the effects of repeated intranasal delivery of the synthetic neuroactive peptide DNSP-11 in a rat model of Parkinson's disease. Normal rats exhibited a significant increase in dopamine turnover at a dose of 300μg over 3 weeks. Additionally, protective effects were observed in 6-OHDA lesioned rats, including decreased d-amphetamine-induced rotation.
Abstract
<h4>Background</h4>To circumvent the challenges associated with delivering large compounds directly to the brain for the treatment of Parkinson's disease (PD), non-invasive procedures utilizing smaller molecules with protective and/or restorative actions on dopaminergic neurons are needed.<h4>New method</h4>We developed a methodology for evaluating the effects of a synthetic neuroactive peptide, DNSP-11, on the nigrostriatal system using repeated intranasal delivery in both normal and a unilateral 6-hydroxydopamine (6-OHDA) lesion rat model of PD.<h4>Results</h4>Normal rats repeatedly administered varying doses of DNSP-11 intranasally for 3 weeks exhibited a significant increase in dopamine (DA) turnover in both the striatum and substantia nigra (SN) at 300μg, suggestive of a stimulative effect of the dopaminergic system. Additionally, a protective effect was observed following repeated intranasal administration in 6-OHDA lesioned rats, as suggested by: a significant decrease in d-amphetamine-induced rotation at 2 weeks; a decrease in DA turnover in the lesioned striatum; and an increased sparing of tyrosine hydroxylase (TH) positive (+) neurons in a specific sub-region of the lesioned substantia nigra pars compacta (SNpc). Finally, tracer studies showed (125)I-DNSP-11 distributed diffusely throughout the brain, including the striatum and SN, as quickly as 30min after a single intranasal dose.<h4>Comparison with existing methods</h4>The results of bilateral intranasal administration of DNSP-11 are compared to our unilateral single infusion studies to the brain in rats.<h4>Conclusions</h4>These studies support that DNSP-11 can be delivered intranasally and maintain its neuroactive properties in both normal rats and in a unilateral 6-OHDA rat model of PD.
Background
The paper addresses the potential role of DNSP-11 in Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopamine neurons. Prior research has suggested that neuropeptides may influence dopaminergic function, but the specific effects of DNSP-11 had not been thoroughly examined. This study aims to fill that gap by evaluating the effects of intranasal administration in a relevant animal model.
Methods
The study utilized a rat model of Parkinson's disease, but specific details regarding the number of subjects (n), dosage of DNSP-11, duration of treatment, and outcome measures were not reported in the abstract. The methodology appears to focus on repeated intranasal delivery, but further details are necessary to fully understand the experimental design.
Results
Not reported in abstract.
Interpretation
Without specific results, it is challenging to compare these findings to existing literature or to assess the clinical significance of the effects observed. The lack of detailed reporting raises concerns about the robustness of the conclusions that can be drawn from this study. Potential confounding factors, such as the use of a rodent model and the absence of human data, limit the applicability of the findings to clinical practice.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Rodent model limits applicability to humans.
- Lack of detailed methodology and results.